Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
The study aims to provide updated information on the genetic factors associated with the diagnoses ‘Diffuse Idiopathic Skeletal Hyperostosis’ (DISH), ‘Ossification of the Posterior Longitudinal Ligament’ (OPLL), and in patients with spinal ligament ossification.
Recent Findings
Recent studies have advanced our knowledge of genetic factors associated with DISH, OPLL, and other spinal ossification (ossification of the anterior longitudinal ligament [OALL] and the yellow ligament [OYL]). Several case studies of individuals afflicted with monogenic disorders, such as X-linked hypophosphatemia (XLH), demonstrate the strong association of fibroblast growth factor 23-related hypophosphatemia with OPLL, suggesting that pathogenic variants in PHEX, ENPP1, and DMP1 are associated with FGF23-phosphate wasting phenotype and strong genetic factors placing patients at risk for OPLL. Moreover, emerging evidence demonstrates that heterozygous and compound heterozygous ENPP1 pathogenic variants inducing ‘Autosomal Recessive Hypophosphatemic Rickets Type 2’ (ARHR2) also place patients at risk for DISH and OPLL, possibly due to the loss of inhibitory plasma pyrophosphate (PPi) which suppresses ectopic calcification and enthesis mineralization.
Summary
Our findings emphasize the importance of genetic and plasma biomarker screening in the clinical evaluation of DISH and OPLL patients, with plasma PPi constituting an important new biomarker for the identification of DISH and OPLL patients whose disease course may be responsive to ENPP1 enzyme therapy, now in clinical trials for rare calcification disorders.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Spinal ligaments, including the anterior and posterior longitudinal spinal ligaments, and the yellow ligament, are essential physiologic tethers which knit together vertebrae to provide the rigidity and flexibility necessary to stiffen an axial spinal column bearing the mechanical loads of bipedal locomotion. Ossifications of the anterior longitudinal ligament (OALL), posterior longitudinal ligament (OPLL), and yellow ligament (OYL) are pathological conditions in which spinal ligaments calcify, unbalancing both upright posture and locomotion, and inducing neurological pain (called myelopathy) due to spinal canal stenosis. Myelopathy most frequently occurs in either OPLL and OYL, due to the location of the spinal cord between the posterior longitudinal ligament and yellow ligament. The prevalence of OPLL is reported to be significantly higher in East Asian populations (0.4–3.0%) than in other ethnicities (0.01–2.0%) [1‐3]. OYL was most prevalent in East Asian populations (16.9–63.9%) [4‐6], with the prevalence in Europe and USA limited to case reports [7‐14]. Many studies have attempted to identify underlying risk factors of OPLL, and multiple genetic and environmental factors have been suggested as disease-causing or disease-modifying agents, but there is little understanding of factors responsible for the heterotopic ossifications in OPLL and DISH, and few effective therapies preventing the progression of the diseases.
Diffuse idiopathic skeletal hyperostosis (DISH) is a specific medical entity which also exhibits ectopic ossifications of spinal ligaments. DISH was first described as ‘ankylosing hyperostosis of the spine’ in 1950 [15], and is characterized by ossification of the ligaments and entheses most commonly in the spine but also in peripheral joints (e.g., Achilles tendon). The diagnostic criteria of DISH first proposed by Resnick and Niwayama require the presence of calcification and ossification along the ventrolateral aspects (i.e., OALL and OPLL) of at least four contiguous vertebral bodies, with or without localized pointed excrescences at intervening vertebral body-disk junctions [16]. Subsequent studies found that patients with severe DISH also tended to exhibit age and sex unmatched osteoporosis of the spine [17‐19]. DISH is more frequent in men and mostly occurs after the age of 40, with a prevalence of 2–4% in the males and females over 40 years of age. The prevalence of DISH rise to 10% or more in those over 70 years of age, and increases to 28% in those over 80 years old [20, 21]. Moreover, DISH often coexists with OPLL, suggesting that shared genetic and environmental risk factors may predispose the development of spinal ligament ossification in both conditions.
Anzeige
Here, we review the literature examining the genetic background of patients with spinal ligament ossifications, and the development of spinal osteoporosis in patients with OPLL and DISH. Our objective is to identify genetic risk factors for OPLL and DISH using insights from the following sources: monogenic and endocrine disorders which induce spinal ligament ossification, disease susceptibility studies assigning genetic risk factors for the development of spinal ligament ossifications, and pathologic variants of related genes (either monoallelic or biallelic) discovered in individuals with spinal ligament ossifications, paying special attention to factors found in patients presenting with the presumptive diagnosis of DISH or OPLL. We also obtained the allelic frequency of each genetic risk factors from Tohoku Medical Megabank Organization (ToMMo) or genome aggregation database (gnomAD). gnomAD is currently the largest collection of population variation from sequencing data of more than 195,000 individuals across the world (http://www.gnomad-sg.org/), while ToMMo provides a collection of Japanese population variation from sequencing data of 38,000 Japanese individuals (https://jmorp.megabank.tohoku.ac.jp/).
Genetic Background of DISH/Spinal Ligament Ossification
Monogenic Disorders Frequently Associated With Spinal Ligament Ossification
X-Linked Hypophosphatemia
X-linked hypophosphatemia (XLH: OMIM #307,800) is a genetic disease caused by inactivating mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX) gene, inducing a fibroblast growth factor-23 (FGF23) mediated hypophosphatemia. The prevalence of XLH is 1 in 20,000 births (0.005%), and is the most common cause of hypophosphatemic rickets [22], and spinal ligament ossification is recognized as one of the most common afflicting comorbidities in XLH patients (Table 1) [23‐25]. Several recent studies involving relatively large numbers of patients identified OPLL in XLH patients, including a cohort study of 59 adult patients with XLH which found OPLL and OYL in five (71%) and four (57%) patients among seven who underwent radiological exam, respectively (Table 1) [26]. Another study, using patient-reported outcomes (PRO) data involving 232 adult patients with XLH, found that 44 patients, or 19%, exhibited spinal stenosis (Table 1) [27]. Finally, our laboratory performed spine computed tomography (CT) on a total of 25 adult patients with XLH, identifying spinal ligament ossification (OALL, OPLL, or OYL) in 20 patients (or 80%), and OPLL in eight patients (or 32%), which is a prevalence of at least 10 times greater than that of OPLL in the general Japanese population (2–4%) [3, 28••]. These observations support the notion that PHEX is a genetic risk factor for spinal ligament ossification (Table 1).
Table 1
Monogenic disorders accompanied with the spinal ligament ossification
XLH, X-linked hypophosphatemia; ARHR1, autosomal recessive hypophosphatemic rickets type 1; ARHR2, autosomal recessive hypophosphatemic rickets type 2; FOP, fibrodysplasia ossificans progressiva; MRI, magnetic resonance imaging; CT, computed tomography; OPLL, ossification of the posterior longitudinal ligament; OYL, ossification of the yellow ligament; NA, not applicable
aTwenty-nine patients underwent imaging studies of the spine
bForty-six patients underwent imaging studies of the spine
cSeven patients underwent imaging studies of the spine
dThis case presented typical phenotype of FOP
eThis case harbored p.K400E mutation and presented only DISH without other phenotypes associated with FOP
Autosomal Recessive Hypophosphatemic Rickets Type 1
Autosomal recessive hypophosphatemic rickets type 1 (ARHR1: OMIM #241,520) is also a member of inherited FGF23-related hypophosphatemia. The causative gene for ARHR1, dentin matrix protein 1 (DMP1), was discovered in 2006 in three families by Lorenz-Depiereux et al. and two families by Feng et al. [37, 38], and spinal ligament ossification was subsequently described in several patients with ARHR1. Case reports of two patients with ARHR1, 66-year-old woman and 78-year-old man, found spinal ligament ossification in the cervical, thoracic, and lumbar spine (Table 1) [29], as did another case report in a 36-year-old proband and two siblings [30]. In the latter study, the proband developed a severe form of OPLL, while his 26-year-old sibling showed a slight ossification in the anterior longitudinal ligament. Additionally, a final case report also found diffuse spinal ligament ossification, including OALL and OPLL, in 45- and 47-year-old patients with ARHR1 (Table 1) [31]. Therefore, ARHR1 is second monogenic disorder in patients with inherited FGF23-related hypophosphatemia that is associated with spinal ligament ossifications.
Autosomal Recessive Hypophosphatemic Rickets Type 2
Biallelic pathogenic variants of Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) have been identified in patients with a third FGF-23 mediated hypophosphatasia called ‘Autosomal Recessive Hypophosphatemic Rickets type 2’ (ARHR2: OMIM #613,312). This is of interest because biallelic pathogenic ENPP1 variants were previously identified in patients with ‘Generalized Arterial Calcification of Infancy’ (GACI). GACI may present as early as the 2nd trimester, and by 6 months of age 50% of the afflicted infants succumb to disease. If affected infants reach 6 months of age, they stabilize, but these patients almost invariably develop ARHR2, which is associated with OPLL in adult patients. ENPP1 is producing plasma inorganic pyrophosphate (PPi) production through enzyme catalysis. Because plasma PPi is a potent inhibitor of ectopic calcification, especially in the medial layers of arterial walls where elastin fibers reside, decreased plasma PPi levels may be an important pathogenic mechanism for the increased collagen fiber calcification seen in spinal ligament ossification of OPLL and DISH. ARHR2 is very rare and only one patient in our laboratory was found with an extremely severe case of OPLL (Table 1) [32, 33]. Although reports of OPLL affecting ARHR2 patients are scarce due to the rarity of ARHR2, tiptoe walking mouse (ttw), first recognized almost 40 years ago as a murine model of OPLL, was later found to possess biallelic ENPP1 loss of function mutations, genetically linking ENPP1 to OPLL [39]. Prospective phenotyping of 20 survivors of GACI further supports an association between ENPP1 and OPLL, in which eight patients with homozygous or compound heterozygous ENPP1 pathogenic variants who developed ARHR2 after surviving GACI were found with enthesopathies in the Achilles tendons or elbow joints, including in relatively young patients, aged 26 and 25 years [40, 41•]. The appearance of enthesopathies in both young ARHR2 patients and ttw mice strongly supports ENPP1 as a genetic risk factor for the development of spinal enthesopathies present in OPLL.
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP: OMIM #135,100) is a rare genetic disease characterized by progressive heterotopic ossification of soft tissues including muscles, tendons, and ligaments. FOP is caused by heterozygous gain-of-function mutation (mainly p. R206H) in the ACVR1 gene which induces altered BMP receptor trafficking resulting in enhanced BMP signaling and ectopic bone formation [42]. Clinical studies identified spinal ligament ossifications, such as OALL or OYL, in FOP patients (Table 1) [34, 35]. Moreover, a recent study discovered a monoallelic p.K400E variant of ACVR1 in a DISH patient, which was confirmed to be pathogenic by functional analysis demonstrating increased BMP signaling through K400E ACVR1 in response to osteogenic BMPs [36•, 43].
Model Animal for DISH
Mice lacking SLC29A1, a nucleotide transporter involved in purine metabolism, exhibit a phenotype similar to DISH [44‐46]. However, unlike ENPP1, spinal ligament ossification resulting from SLC29A1 mutations have not been reported in human to date.
Endocrine Disorders Frequently Accompanied With the Spinal Ligament Ossification
Some endocrine disorders such as acromegaly, hypoparathyroidism, pseudohypoparathyroidism, and familial hypocalciuric hypercalcemia (FHH) have been reported to be associated with DISH or spinal ligament ossification,. Acromegaly is a disorder caused by the development of growth hormone (GH)-producing pituitary adenoma, resulting in increased GH and insulin-like growth factor-1 (IGF-1). Spinal ligament ossification has been reported in some acromegaly patients [47, 48], while another study of 30 acromegaly patents found a high incidence of DISH (47%) [49]. However, a direct association between acromegaly and OPLL was never established due to patient selection bias. A recent study by Hoshino et al. from our group evaluated CT spinal data from ten consecutive patients with acromegaly, discovering spinal ligament ossification in five patients (50%) [50]. In this report, factors associated with spinal ligament ossification, such as age and body mass index (BMI), and clinical activity of acromegaly such as GH and IGF-1 were compared in patients with and without spinal ligament ossifications, revealing that BMI was the only significant factor differentiating the two groups. While the number of patients in this study was not sufficient to establish significance, the study suggested that acromegaly and mutations in genes inducing familial gigantism, such as AIP, GPR101, GNAS, MEN1, and PRKAR1A, may be risk factors for the development of spinal ligament ossifications [51].
There are several case reports associating patients with long-term untreated hypoparathyroidism, pseudohypoparathyroidism, or FHH with spinal ligament ossifications [52‐62]. In addition to these case reports, a study of 17 patients with hypoparathyroidism reported that nine patients (53%) presented with spinal ligament ossifications [63]. These disorders, which affect calcium metabolism, may be another predisposing condition for spinal ligament ossifications.
Anzeige
Disease Susceptibility Genes for Spinal Ligament Ossification
To date, numerous genetic studies of OPLL patients investigating disease susceptibility genes have revealed genetic risk factors for the development of OPLL (Table 2). We review some important genes for bone and cartilage formation from candidate gene association studies below.
Table 2
Genes and variants susceptible to spinal ligament ossifications
DISH, diffuse idiopathic spinal hyperostosis; OPLL, ossification of the posterior longitudinal ligament; MAF, minor allele frequency; gnomAD, genome aggregation database; ToMMo, Tohoku Medical Megabank Organization; OR, odds ratio; NA, not applicable; GWAS, genome-wide association study
aAn odds ratio in codominant model
bA significant association was observed only in male patients
cThis SNP was associated with the extent of OPLL
dA significant association was observed only in female patients
eVariant information was described as the original version because the allele at the reported location was different in GRCh38 or variant was not recorded in dbsnp database
fLocated within 1 Mb of SNP significantly associated with OPLL
gA significant association was observed only in Japanese patients with DISH
hThree patients with DISH were included
COL11A2 encodes collagen type XI alpha 2 chain, which is the main collagenous component of cartilage. Variants of this gene were associated with OPLL (promoter [− 182] A > C [the allele at promoter [− 182] is C in GRCh38]); therefore, the actual SNP introduced in this article is uncertain. The nearest reported SNP (A > C) around the promoter [− 182] is rs1799905 (promoter [− 186], rs1799907, rs1799910, rs1799911) in a candidate gene association study involving 137 Japanese cases and 183 controls [80]. Another candidate gene association study involving 195 Japanese cases and 187 controls found that a novel SNP in COL11A2 (rs1417877815) along with the abovementioned SNP (rs1799907) was associated with OPLL [81]. Additionally, COL6A1 was reportedly associated with OPLL in some candidate gene association studies (Table 2) [76‐79].
One of the key regulators of bone metabolism, BMP2, is reportedly associated with OPLL. Several SNPs in BMP2 (rs3178250, rs2273073, rs235768, rs1049007) or SNPs located upstream or downstream of BMP2 (rs1116867, rs965291) are reported to be significantly associated with the occurrence or the severity of OPLL in several candidate gene association studies involving Chinese patients and control subjects [67‐70]. Moreover, mutation analysis without control subjects using targeted next-generation sequencing revealed a deleterious coding variant of BMP2 with rare allele frequencies among a total of 50 Chinese patients with OPLL (rs1464127693) [104]. However, another candidate gene association study of 162 Korean patients and 159 control subjects failed to reconfirm the association of some BMP2 SNPs previously associated with OPLL, specifically rs2273073 and rs10490007 [78]. In addition to BMP2, there were a sib-pair linkage study and some candidate gene association studies reporting an association between BMP member (BMP4 and BMP9) and OPLL (Table 2) [71‐73, 104].
TGFβ1 protein is another key protein regulating bone and cartilage formation. Kamiya et al. firstly disclosed the possible association between a TGFβ1 SNP (rs1800470) and OPLL in a candidate gene association study involving 46 Japanese patients and 273 control subjects [98], but this association was not confirmed by Han et al. in a candidate gene association study of 98 Korean patients and 200 control subjects [105]. Another candidate gene association study involving 369 Japanese patients and 258 control subjects also failed to associate the above-mentioned TGFβ1 SNP (rs1800470) with OPLL, reporting instead that more than half of the patients harboring TGFβ1 SNP (rs1800470) presented with OPLL that was not limited to cervical spine while most patients with a wild-type allele presented with OPLL limited to the cervical spine [106]. Therefore, this SNP might be a factor related to the area of the ossified lesion in the total spine in OPLL patients [106].
While a candidate gene association study selects a few genes as target genes for the analysis, a genome-wide association study (GWAS) comprehensively analyzes all genes, leading to the less biased information on the genetic factors associated with OPLL. The GWAS of OPLL involving 1130 Japanese patients and 7135 controls revealed SNPs in additional genes [75•]. While the odds ratios (ORs) for these SNPS with OPLL were not so high, SNPs in CCDC91 (rs1979679, OR: 1.30), HAO1 (rs2423294, OR: 1.43), and RSPO2 (rs374810, OR: 1.35) were identified as increasing susceptibility. Additionally, increased gene expressions of RSPH9 and STK38L, located within 1 Mb from rs927485 (OR: 1.37) and rs11045000 (OR: 1.32), respectively, were confirmed in osteoblasts, suggesting that these genes may be relevant for membranous ossification.
While the genetic background of OPLL is well established, the genetic factors associated with DISH are less so. A candidate gene association study in 97 Japanese DISH patients and 298 controls, and in 96 Czech DISH patients and 96 controls, revealed that a COL6A1 SNP (rs35796750) already identified in OPLL was also associated with DISH in Japanese patients, although this association was undetected in Czech patients [76, 102]. Additionally, a recent study in Portugal utilized a mutational analysis via whole-exome sequencing in four patients with DISH to identify candidate pathogenic variants, followed by an association study of 65 patients and 118 control subjects, identifying SNP (rs34473844) in PPP2RD to be associated with DISH [103]. Moreover, because the clinical manifestation of DISH sometimes overlaps with OPLL, studies on the genetic factors of DISH were performed using cohorts of OPLL patients including cases who presented with imaging findings suggestive of DISH. For example, another candidate gene association study of FGF2 and FGFR in 157 Korean OPLL patients including three patients with DISH and 222 controls reported that FGF2 SNPs (rs1476217, rs3747676) were significantly associated with DISH [87].
Heterozygote or Compound Heterozygote of the Mutation in Causative Genes Identified in the Monogenic Disorders Frequently Accompanied With the Spinal Ligament Ossification
After the identification of ENPP1 as the causative gene in ttw mice with a severe OPLL phenotype, the same investigators searched for pathogenic ENPP1 variants in 323 Japanese patients with OPLL, identifying 10 candidates (NC_000006.12:g.131808012G > A [rs1800949], NC_000006.12:g.131807739_131807740delAA [rs1799773], NC_000006.12:g.131808012G > A [rs1800948], c.179 T > C [rs1781304340], c.517A > C [rs1044498], c.802 T > C [rs17847050], c.860C > T [rs190947144], c.915 + 27 T > G [rs9493113], c.2101-11delT [rs397832689], c.2335A > C [rs1805138]) (Fig. 1) [83]. These pathogenic ENPP1 variants occurred as monoallelic, biallelic, or compound heterozygous variants in OPLL patients, suggesting an association of ENPP1 with the development of OPLL. The candidate variants were further assessed in an association study involving 332 control subjects, identifying only one variant (rs397832689) to be significantly associated with OPLL (Fig. 1) [83]. A second candidate gene association study involving 180 Japanese patients and 265 controls also reported a second SNP in ENPP1 (c.1566-14 T > C [rs75272847]) to be associated with OPLL (Fig. 1) [84].
Fig. 1
The location and allelic information of variants in ENPP1 gene detected in patients with OPLL. A The schematic image of ENPP1 protein and the location of each variant. B Bottom part: the list of allelic information and clinical phenotype of the ENPP1 variants detected in the patients with OPLL or osteoporosis. SMB, somatomedine B; AA, amino acid; MAF, minor allele frequency; OPLL, ossification of the posterior longitudinal ligament; DISH, diffuse idiopathic skeletal hyperostosis; EOP, early onset osteoporosis. Variant information is provided in accordance with GRCh38
Recently, we described three patients with heterozygous or compound heterozygous ENPP1 pathogenic variants (rs2273411 [GnomAD: 0.00010, ToMMo: 0.00071], rs201519006 [GnomAD: 0.00016, ToMMo: 0.0055]), who did not present with a GACI or ARHR2 clinical phenotype (Fig. 1). However, a patient with the a monoallelic ENPP1 pathogenic variant (rs2273411) was found to have early onset male osteoporosis, and a second patient with a monoallelic ENPP1 pathogenic variant (rs201519006) presented with DISH. Additionally, a third patient with compound biallelic ENPP1 pathogenic variants (rs2273411/rs20159006) exhibited severe DISH/OPLL and enthesopathies in the Achilles’ tendon and around hip joints (Fig. 1) [107••]. In vitro analysis of the catalytic velocity in these ENPP1 variants confirmed decreased catalytic activity, a finding also supported by the decreased plasma PPi levels observed in these patients (which is generated by the ENPP1 hydrolysis of ATP). This study also evaluated the presence of ectopic ossifications in family members of probands, identifying 23-year-old and 19-year-old male siblings harboring monoallelic ENPP1 pathogenic variants who also possessed slight Achilles tendon enthesopathies but not OPLL. Interestingly, another study detected monoallelic pathogenic ENPP1 variants previously identified in GACI patients with biallelic ENPP1 deficiency (rs148462924 [GnomAD: 0.00011, ToMMo: not listed], rs147346173 [GnomAD: 0.00026, ToMMo: not listed]), but the monoallelic patients (60- and 69-year-old males) exhibited early-onset osteoporosis and multiple vertebral compression fractures. These findings of early onset osteoporosis and increased fracture risk were recapitulated in a mouse model of homozygous ENPP1 deficiency (Fig. 1) [108••]. The combined data suggests that monoallelic ENPP1 deficiency is a causative genetic factor inducing low bone mass.
Anzeige
The allelic frequency of previously reported pathogenic variants of ENPP1 (rs2273411, rs20159006, rs148462924, rs147346173) detected in patients with OPLL or early-onset osteoporosis was as high as 0.5%. This frequency is much higher than the prevalence of monogenic disorders (i.e., XLH, ARHR1, and ARHR2), which are very rare (0.005%). In addition, the allele frequency of variants of susceptible genes identified by GWAS and association studies is about 30–40% (Table 2). Generally, the pathogenicity of the variants are inversely correlated with the allele frequency.
Hence, the clinical impact of pathogenic ENPP1 variants in monoallelic or compound biallelic patients on spinal ossification and spinal osteoporosis are midway between the more prevalent susceptible variants identified by GWAS or case–control studies (weak effect), and the less prevalent biallelic or compound monoallelic ENPP1 and DMP1 pathogenic variants in autosomal recessive GACI and ARHR1 patients (strong effect) (Fig. 2).
Fig. 2
Schematic image of the clinical relevance to the spinal ligament ossification of susceptibility genes and genes responsible for monogenic diseases
In this review, we focused on studies identifying genetic factors associated with spinal ligament ossifications. In monogenic diseases, the high frequencies of spinal ligament ossification occurring in XLH, ARHR1, and ARHR2 were reviewed. Hemizygous or heterozygous PHEX mutations and biallelic pathogenic variants of ENPP1 and DMP1 are strong genetic factors predisposing patients for spinal ligament ossification (Fig. 2). Biallelic ENPP1 mutations, although rare, induce severe spinal ligament ossifications, whereas patients with monoallelic ENPP1 pathogenic variants exhibit less severe spinal enthesopathies and have a reduced genetic risk of DISH and OPLL (Fig. 2). Finally, not all patients with monoallelic ENPP1 deficiency exhibit spinal ligament ossification, suggesting that other susceptible variants in the variable genes detected by association studies (e.g., GWAS) and environmental factors (e.g., focal inflammation, diabetes mellitus, chronic trauma) may further modify the predisposition for spinal ligament ossifications [109].
Because PHEX, DMP1, and ENPP1 all induce FGF23-related hypophosphatemia, they may affect common pathophysiological mechanisms inducing enthesopathies and spinal ligament ossifications. A Japanese study of OPLL patients reported that increased plasma FGF23 and lower plasma phosphate are associated with more rapidly progressing OPLL, additionally supporting FGF23 associated hypophosphatemia as a pathogenic mechanism for spinal enthesopathy [110, 111••]. Moreover, spinal ligament ossifications in patients with non-FGF23 mediated chronic hypophosphatemia are not increased. For example, patients with chronic FGF23-non-related hypophosphatemia (e.g., Fanconi syndrome, vitamin D deficiency) do not develop ectopic ossifications. Additionally, other forms of FGF23-related hypophosphatemia (e.g., tumor-induced osteomalacia or autosomal dominant hypophosphatemic rickets) are also not associated with spinal ligament ossification. We therefore hypothesized that unidentified mechanisms independent of serum phosphate and FGF23 in common with PHEX, DMP1, and ENPP1 may be responsible.
Anzeige
While the precise functions of PHEX and DMP1, even from the viewpoint of phosphate metabolism, remained to be elucidated, one definite function of ENPP1 is producing plasma PPi — a potent inhibitor of ectopic calcification — through enzyme catalysis, and the regulating the bone mass via catalytic-independent pathways [112]. Plasma PPi is markedly decreased in GACI and ARHR2 patients with biallelic ENPP1 deficiency, and mildly reduced in the patients with monoallelic ENPP1 deficiency [107••, 108••]. Moreover, plasma PPi in the Hyp mouse, a murine model of XLH induced by PHEX mutations, is also reported to be decreased, supporting the notion that reduced plasma PPi may induce the enthesopathies in XLH and ARHR2, resulting in spinal ossification and an OPLL phenotypes in these diseases [113]. A recent study demonstrated that recombinant ENPP1 normalized plasma PPi and prevented enthesopathies in murine biallelic ENPP1 deficiency, also supporting the hypothesis that plasma PPi levels prevent enthesopathies [41•]. However, patients with homozygous inactivating mutations of ABCC6 coding for the ABCC6 protein which promotes the cellular efflux of ATP may also develop GACI or pseudoxanthoma elasticum. These patients also exhibit low PPi levels but not ectopic ossifications such as spinal ligament ossifications. However, because plasma PPi in murine models of homozygous ENPP1 and ABCC6 deficiency are reduced to 10% and 30% of wild type, respectively, the difference in the prevalence of spinal ligament ossifications in these conditions may be related to the differences in plasma PPi levels [108••, 114].
In addition to the genes associated with monogenic disorders and susceptible genes, acromegaly may be another relatively strong risk factor for spinal ligament ossification. Increased GH receptors in bone osteoblasts and insulin growth factor 1-induced osteogenic differentiation are proposed as the putative mechanisms for spinal ligament ossification in the patients with acromegaly [115, 116]. However, as with XLH, ARHR1, and ARHR2, not all acromegaly patients exhibit spinal ligament ossification [50]. Thus, acromegaly and the associated genes may be categorized as a relatively strong factors equivalent to heterozygous ENPP1 deficiency.
Many case–control and GWAS studies have been conducted to identify OPLL susceptible genes, along with fewer studies focused on DISH, all mainly conducted in East Asia (Table 2). Because OPLL sometimes causes myelopathy due to spinal cord compression, patients with OPLL often visit hospitals and undergo surgery. As the clinical manifestations among some patients with OPLL, disease animal models and genetic studies (candidate gene association studies and GWAS) have been actively explored to elucidate the etiology of the disease and to develop treatment. On the other hand, regarding DISH, its prevalence is as high as 20–30% in the elderly [20, 21], and symptoms include impaired vertebral rotation and reduced bone mineral density in the vertebrae, sometimes leading to fractures. However, the affected paraspinal ligaments are mainly the anterior longitudinal ligaments among patients with DISH, and spinal cord compression is rarely observed, so there are fewer hospital visits and fewer opportunities for surgery compared to OPLL. As the clinical manifestations of DISH are mild, there might be less concern about exploring etiology and developing treatment, and the small number of patients visiting hospitals might also hinder a large-scale genetic study. Among the identified susceptible genes for OPLL, COL11A2 — the main collagenous component of cartilage — is speculated to play a protective role in ectopic ossification [80, 81, 117]. COL6A1 is a protein providing the structural support for osteoblasts or chondrocytes, and also plays a role in membranous or endochondral ossification [21]. Because COL6A1 was identified as a susceptible gene in both OPLL and DISH, it may play a crucial role in the ossification process common to both disorders. BMP members, such as BMP2, BMP4, and BMP9, bind to receptors and activate several pathways, resulting in the transcription of proteins which promote proliferation and differentiation of mesenchymal stem cells, osteoblasts, and chondrocytes [21]. It is, therefore, highly probable that enhanced BMP signaling is associated with OPLL, a finding also supported by the identification of the p.K400E ACVR1 activating variant which increases BMP signaling and is associated with DISH [42]. Among the identified susceptible genes for DISH, FGF2 transmits signals through FGFR2 and FGFR3, and FGF/FGFR is a major signal pathway involved in the bone formation [21].
Our laboratory identified that monoallelic and compound biallelic ENPP1 pathogenic variants have moderate effects on spinal ligament ossification (Fig. 2). Therefore, ENPP1 enzyme replacement therapy may be a promising therapeutic strategy for treating OPLL/DISH in these patients. ENPP1-Fc enzyme replacement rescues murine models of GACI and ARHR2, including the low bone mass, lethal arterial calcifications, and the Achilles tendon enthesopathies observed in these models [41•, 118]. A clinical grade therapy is now in clinical development (INZ-701, Inozyme Pharma, Boston, MA) for patients with GACI, ARHR2, and PXE, and may be available to clinicians for other indications for the near future. Additionally, reference plasma PPi levels were recently established in children and adolescents aged 0 to 18 years of age, enabling plasma PPi as a predictive biomarker [119]. Measurement of plasma PPi, therefore, may efficiently screen patients with the spinal ligament ossifications for ENPP1 deficiency.
Anzeige
In conclusion, related monogenic disorders of hypophosphatasia and acromegaly should be screened in the clinical assessment of patients with OPLL/DISH, and plasma PPi is a new biomarker enabling clinicians to screen OPLL/DISH patients for ENPP1 deficiency. Finally a therapeutic biologic ENPP1-Fc may be a promising therapy for patients suffering from spinal enthesopathies such as OPLL/DISH. The identification of common pathogenic mechanisms in monogenic and endocrine disorders associated with OPLL/DISH, and the development of targeting therapeutics for other relevant pathways such as ACVR1, COL11A2, COL6A, BMP2,4,9, and TGF-β1 are remaining important questions to be addressed.
Declarations
Conflict of Interest
D. T. B. is an inventor listed on patents owned by Yale University for therapeutics treating ENPP1 deficiency, and is an equity holder and receives research and consulting support from Inozyme Pharma, Inc.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Matsunaga S, Sakou T. Ossification of the posterior longitudinal ligament of the cervical spine: etiology and natural history. Spine (Phila Pa 1976). 2012;37:309–14.CrossRef
2.
Fujimori T, Le H, Hu SS, Chin C, Pekmezci M, Schairer W, et al. Ossification of the posterior longitudinal ligament of the cervical spine in 3161 patients: a CT-based study. Spine (Phila Pa 1976). 2015;40:E394-403.PubMedCrossRef
3.
Abiola R, Rubery P, Mesfin A. Ossification of the posterior longitudinal ligament: etiology, diagnosis, and outcomes of nonoperative and operative management. Global Spine J. 2015;6:195–204.PubMedPubMedCentralCrossRef
4.
Mori K, Kasahara T, Mimura T, Nishizawa K, Murakami Y, Matsusue Y, et al. Prevalence, distribution, and morphology of thoracic ossification of the yellow ligament in Japanese; results of CT-based cross-sectional study. Spine (Phila Pa 1976). 2013;38:E1216-22.PubMedCrossRef
5.
Lang N, Yuan HS, Wang HL, Liao J, Li M, Guo FX, et al. Epidemiological survey of ossification of the ligamentum flavum in thoracic spine: CT imaging observation of 993 cases. Eur Spine J. 2013;22:857–62.PubMedCrossRef
6.
Moon BJ, Kuh SU, Kim S, Kim KS, Cho YE, Chin DK. Prevalence, distribution, and significance of incidental thoracic ossification of the ligamentum flavum in Korean patients with back or leg pain: MR-based cross sectional study. J Korean Neurosurg Soc. 2015;58:112–8.PubMedPubMedCentralCrossRef
7.
Arafat QW, Jackowski A, Chavda SV, West RJ. Case report: ossification of the thoracic ligamenta flava in a Caucasian: a rare cause of myelopathy. Br J Radiol. 1993;66:1193–6.PubMedCrossRef
8.
Pascal-Mousselard H, Smadja D, Cabre P, Raynaud M, Catonne Y. Ossification of the ligamenta flava with severe myelopathy in a black patient. A case report. Spine (Phila Pa 1976). 1998;23:1607–8.PubMedCrossRef
9.
Van Oostenbrugge RJ, Herpers MJ, De Kruijk JR. Spinal cord compression caused by unusual location and extension of ossified ligamenta flava in a Caucasian male. A case report and literature review. Spine (Phila Pa 1976). 1999;24:486–8.PubMedCrossRef
10.
Debiais F, Bataille B, Debiais P, Azais I, Bontoux D, Alcalay M. Femoral neuropathy secondary to ossification of the ligamentum flavum. J Rheumatol J Rheumatol. 2000;27:1313–4.PubMed
11.
Celli P, Caroli E, Trillò G, Ferrante L, Mariatos P. Ossification of the ligamentum flavum in a Caucasian. Case report J Neurosurg Sci. 2002;46:96–9.PubMed
12.
Tokala DP, Lam KS, Prince HG. Ossification of the proximal thoracic ligamenta flava causing acute myelopathy in a Caucasian: case report and literature review. Spinal Cord. 2007;45:310–3.PubMedCrossRef
13.
Xu R, Sciubba DM, Gokaslan ZL, Bydon A. Ossification of the ligamentum flavum in a Caucasian man. J Neurosurg Spine. 2008;9:427–37.PubMedCrossRef
14.
Ricciardi GA, Garfinkel IG, Carrioli GG, Ricciardi DO. Thoracic ligamentum flavum ossification: a rare cause of spinal cord injury without tomographic evidence of trauma in a Caucasian patient. Case report and literature review. Spinal Cord Ser Cases. 2021;7:57.PubMedPubMedCentralCrossRef
15.
Forestier J, Rotes-Querol J. Senile ankylosing hyperostosis of the spine. Ann Rheum Dis. 1950;9:321–30.PubMedPubMedCentralCrossRef
16.
Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis (DISH): Forestier’s disease with extraspinal manifestations. Radiology. 1975;115:513–24.PubMedCrossRef
17.
Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J. 2009;18:145–56.PubMedCrossRef
18.
Caron T, Bransford R, Nguyen Q, Agel J, Chapman J, Bellabarba C. Spine fractures in patients with ankylosing spinal disorders. Spine (Phila Pa 1976). 2010;35:E458-64.PubMedCrossRef
19.
Liu P, Yao Y, Liu MY, Fan WL, Chao R, Wang ZG, et al. Spinal trauma in Mainland China from 2001 to 2007: an epidemiological study based on a nationwide database. Spine (Phila Pa 1976). 2012;37:1310–5.PubMedCrossRef
Dabrowski M, Kubaszewski Ł. Diffuse idiopathic skeletal hyperostosis of cervical spine with dysphagia-molecular and clinical aspects. Int J Mol Sci. 2021;22:4255.PubMedPubMedCentralCrossRef
22.
Rothenbuhler A, Schnabel D, Högler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103: 153892.CrossRef
23.
Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology. 1989;171:403–14.PubMedCrossRef
24.
Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int. 2009;85:235–46.PubMedPubMedCentralCrossRef
25.
Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174:325–33.PubMedCrossRef
26.
Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41:865–76.PubMedPubMedCentralCrossRef
27.
Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3:1321–34.PubMedPubMedCentralCrossRef
28.
•• Kato H, Koga M, Kinoshita Y, Taniguchi Y, Kobayashi H, Fukumoto S, et al. Incidence of complications in 25 adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2021;106:E3682–92. An important study documenting that the prevalence of spinal ligament ossifications and osteoarthritis is higher among adult patients with XLH than that among Japanese general population.PubMedCrossRef
29.
Mäkitie O, Pereira RC, Kaitila I, Turan S, Bastepe M, Laine T, et al. Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Miner Res. 2010;25:2165–74.PubMedPubMedCentralCrossRef
30.
Karaplis AC, Bai X, Falet JP, Macica CM. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology. 2012;153:5906–17.PubMedPubMedCentralCrossRef
31.
Gannagé-Yared MH, Makrythanasis P, Chouery E, Sobacchi C, Mehawej C, Santoni FA, et al. Exome sequencing reveals a mutation in DMP1 in a family with familial sclerosing bone dysplasia. Bone. 2014;68:142–5.PubMedCrossRef
32.
Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T. Case Report A patient with hypophosphatemic rickets and ossi fi cation of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone. 2011;49:913–6.PubMedCrossRef
33.
Hirao Y, Chikuda H, Oshima Y, Matsubayashi Y, Tanaka S. Extensive ossification of the paraspinal ligaments in a patient with vitamin D-resistant rickets: case report with literature review. Int J Surg Case Rep. 2016;27:125–8.PubMedPubMedCentralCrossRef
34.
Connor JM, Skirton H, Lunt PW. A three generation family with fibrodysplasia ossificans progressiva. J Med Genet. 1993;30:687–9.PubMedPubMedCentralCrossRef
35.
Barnett CP, Dugar M, Haan EA. Late-onset variant fibrodysplasia ossificans progressiva leading to misdiagnosis of ankylosing spondylitis. Am J Med Genet A. 2011;155A:1492–5.PubMedCrossRef
36.
• Gupta A, Zimmermann MT, Wang H, Broski SM, Sigafoos AN, Macklin SK, et al. Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification. Am J Med Genet A. 2019;179:1764–77. An interesting study reporting the novel ACVR1 variants in patients with DISH.PubMedCrossRef
37.
Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248–50.PubMedPubMedCentralCrossRef
38.
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–5.PubMedPubMedCentralCrossRef
39.
Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998;19:271–3.PubMedCrossRef
40.
Ferreira CR, Hackbarth ME, Ziegler SG, Pan KS, Roberts MS, Rosing DR, et al. Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet Med. 2021;23:396–407.PubMedCrossRef
41.
• Ferreira CR, Ansh J, Nester C, O’Brien C, Stabach P, Murtada S, et al. Musculoskeletal comorbidities and quality of life in ENPP1-deficient adults and the response of enthesopathy to enzyme replacement therapy in murine models. J Bone Miner Res. 2022;37:494–504. An interesting study evaluating the epreventive effect of ENPP1 replacement therapy on ENPP1 deficient mice.PubMedCrossRef
42.
Serrano De La Peña L, Billings PC, Fiori JL, Ahn J, Kaplan FS, Shore EM. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res. 2005;20:1168–76.CrossRef
43.
Tsukamoto S, Kuratani M, Katagiri T. Functional characterization of a unique mutant of ALK2, p.K400E, that is associated with a skeletal disorder, diffuse idiopathic skeletal hyperostosis. Bone. 2020;137:115410.PubMedCrossRef
44.
Warraich S, Bone DBJ, Quinonez D, Ii H, Choi DS, Holdsworth DW, et al. Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. J Bone Miner Res. 2013;28:1135–49.PubMedCrossRef
45.
Daniels G, Ballif BA, Helias V, Saison C, Grimsley S, Mannessier L, et al. Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization. Blood. 2015;125:3651–4.PubMedPubMedCentralCrossRef
46.
Ii H, Warraich S, Tenn N, Quinonez D, Holdsworth DW, Hammond JR, et al. Disruption of biomineralization pathways in spinal tissues of a mouse model of diffuse idiopathic skeletal hyperostosis. Bone. 2016;90:37–49.PubMedCrossRef
47.
Schmidt RF, Goldstein IM, Liu JK. Ossified ligamentum flavum causing spinal cord compression in a patient with acromegaly. J Clin Neurosci. 2013;20:1599–603.PubMedCrossRef
48.
Kamakura D, Fukutake K, Nakamura K, Tsuge S, Hasegawa K, Tochigi N, et al. Acromegaly presenting with myelopathy due to ossification of posterior longitudinal ligament: a case report. BMC Musculoskelet Disord. 2021;22:353.PubMedPubMedCentralCrossRef
49.
Littlejohn GO, Hall S, Brand CA, Davidson A. New bone formation in acromegaly: pathogenetic implications for diffuse idiopathic skeletal hyperostosis. Clin Exp Rheumatol. 1986;4:99–104.PubMed
50.
Hoshino Y, Hidaka N, Kato H, Koga M, Taniguchi Y, Kobayashi H, et al. Incidence of ossification of the spinal ligaments in acromegaly patients. Bone Rep. 2022;17: 101628.PubMedPubMedCentralCrossRef
51.
Beckers A, Petrossians P, Hanson J, Daly AF. The causes and consequences of pituitary gigantism. Nat Rev Endocrinol. 2018;14:705–20.PubMedCrossRef
52.
Cullen DR, Pearce JM. Spinal cord compression in pseudohypoparathyroidism. J Neurol Neurosurg Psychiatry. 1964;27:459–62.PubMedPubMedCentralCrossRef
53.
Firooznia H, Golimbu C, Rafii M. Case report 312. Diagnosis: progressive paraparesis in a woman with pseudohypoparathyroidism (PHP) with ossification of the posterior longitudinal ligament from C4 to T5. Skeletal Radiol. 1985;13:310–3.PubMedCrossRef
Yamamoto Y, Noto Y, Saito M, Ichizen H, Kida H. Spinal cord compression by heterotopic ossification associated with pseudohypoparathyroidism. J Int Med Res. 1997;25:364–8.PubMedCrossRef
56.
Iwase T, Nokura K, Mizuno T, Inagaki T. Spastic tetraparesis in a patient with pseudopseudohypoparathyroidism. J Neurol. 2002;249:1457–8.PubMedCrossRef
57.
Chen H, Tseng F, Su D, Chen H, Tsai K. Multiple intracranial calcifications and spinal compressions: rare complications of type la pseudohypoparathyroidism. J Endocrinol Invest. 2005;28:646–50.PubMedCrossRef
Jiang Y, Hu H, Ye X, Peng J, He H, Xu G, et al. Multilevel myelopathy associated with pseudohypoparathyroidism simulating diffuse skeletal hyperostosis: a case report and literature review. Spine. 2010;35:E1355–8.PubMedCrossRef
60.
Li P, Huang L, Zhao Z, Ye X, Liu Z. Spinal-cord compression related to pseudohypoparathyroidism. J Clin Neurosci. 2011;18:143–5.PubMedCrossRef
61.
Rivas AM, Lado-Abeal J. Diffuse idiopathic skeletal hyperostosis and familial hypocalciuric hypercalcemia: a unique association in a young female. Am J Med Sci. 2013;346:247–9.PubMedCrossRef
62.
John DR, Suthar PP. Radiological features of long-standing hypoparathyroidism. Pol J Radiol. 2016;81:42–5.PubMedPubMedCentralCrossRef
63.
Okazaki T, Takuwa Y, Yamamoto M, Matsumoto T, Igarashi T, Kurokawa T, et al. Ossification of the paravertebral ligaments: a frequent complication of hypoparathyroidism. Metabolism. 1984;33:710–3.PubMedCrossRef
64.
Kim DH, Yun DH, Kim HS, Min SK, Yoo SD, Lee KH, et al. The insertion/deletion polymorphism of angiotensin I converting enzyme gene is associated with ossification of the posterior longitudinal ligament in the Korean population. Ann Rehabil Med. 2014;38:1–5.PubMedPubMedCentralCrossRef
65.
Horikoshi T, Maeda K, Kawaguchi Y, Chiba K, Mori K, Koshizuka Y, et al. A large-scale genetic association study of ossification of the posterior longitudinal ligament of the spine. Hum Genet. 2006;119:611–6.PubMedCrossRef
66.
Chon J, Hong JH, Kim J, Han YJ, Lee BW, Kim SC, et al. Association between BH3 interacting domain death agonist (BID) gene polymorphism and ossification of the posterior longitudinal ligament in Korean population. Mol Biol Rep. 2014;41:895–9.PubMedCrossRef
67.
Hao W, Zhao-hui Y, Dong-mei L, Ling W, Xiang-long M, Bao-peng T. Association between two polymorphisms of the bone morpho-genetic protein-2 gene with genetic susceptibility to ossification of the posterior longitudinal ligament of the cervical spine and its severity. Chin Med J. 2008;121:1806–10.CrossRef
68.
Wang H, Liu D, Yang Z, Tian B, Li J, Meng X, et al. Association of bone morphogenetic protein-2 gene polymorphisms with susceptibility to ossification of the posterior longitudinal ligament of the spine and its severity in Chinese patients. Eur Spine J. 2008;17:956–64.PubMedPubMedCentralCrossRef
69.
Yan L, Zhao WG, Li JJ, Yang H, Wang H, Lin X. Linkage of three polymorphisms on chromosome 20p12 to ossification of the posterior longitudinal ligament of spine and its severity in Han Chinese patients. Chin Med J. 2010;123:2341–6.PubMed
70.
Yan L, Chang Z, Liu Y, Li YB, He BR, Hao DJ. A single nucleotide polymorphism in the human bone morphogenetic protein-2 gene (109T>G) affects the Smad signaling pathway and the predisposition to ossification of the posterior longitudinal ligament of the spine. Chin Med J. 2013;126:1112–8.PubMed
71.
Meng XL, Wang H, Yang H, Hai Y, Tian BP, Lin X. T allele at site 6007 of bone morphogenetic protein-4 gene increases genetic susceptibility to ossification of the posterior longitudinal ligament in male Chinese Han population. Chin Med J. 2010;123:2537–42.PubMed
72.
Ren Y, Feng J, Liu ZZ, Wan H, Li JH, Lin X. A new haplotype in BMP4 implicated in ossification of the posterior longitudinal ligament (OPLL) in a Chinese population. J Orthop Res. 2012;30:748–56.PubMedCrossRef
73.
Ren Y, Liu Z, Feng J, Wan H, Li J, Wang H, et al. Association of a bmp9 haplotype with ossification of the posterior longitudinal ligament (OPLL) in a chinese population. PLoS One. 2012;7:e40587.PubMedPubMedCentralCrossRef
74.
Wang H, Jin W, Li H. Genetic polymorphisms in bone morphogenetic protein receptor type IA gene predisposes individuals to ossification of the posterior longitudinal ligament of the cervical spine via the smad signaling pathway. BMC Musculoskelet Disord. 2018;19:61.PubMedPubMedCentralCrossRef
75.
• Nakajima M, Takahashi A, Tsuji T, Karasugi T, Baba H, Uchida K, et al. A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. Nat Genet. 2014;46:1012–6. This study performs the largest scale GWAS for the susceptibility gene of OPLL.PubMedCrossRef
76.
Tanaka T, Ikari K, Furushima K, Okada A, Tanaka H, Furukawa K-I, et al. Genomewide linkage and linkage disequilibrium analyses identify COL6A1, on chromosome 21, as the locus for ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet. 2003;73:812–22.PubMedPubMedCentralCrossRef
77.
Kong Q, Ma X, Li F, Guo Z, Qi Q, Li W, et al. COL6A1 polymorphisms associated with ossification of the ligamentum flavum and ossification of the posterior longitudinal ligament. Spine. 2007;32:2834–8.PubMedCrossRef
78.
Kim KH, Kuh SU, Park JY, Lee SJ, Park HS, Chin DK, et al. Association between BMP-2 and COL6A1 gene polymorphisms with susceptibility to ossification of the posterior longitudinal ligament of the cervical spine in Korean patients and family members. Genet Mol Res. 2014;13:2240–7.PubMedCrossRef
79.
Wang P, Liu X, Zhu B, Ma Y, Yong L, Teng Z, et al. Association of IL17RC and COL6A1 genetic polymorphisms with susceptibility to ossification of the thoracic posterior longitudinal ligament in Chinese patients. J Orthop Surg Res. 2018;13:109.
80.
Koga H, Sakou T, Taketomi E, Hayashi K, Numasawa T, Harata S, et al. Genetic mapping of ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet. 1998;62:1460–7.PubMedPubMedCentralCrossRef
81.
Maeda S, Ishidou Y, Koga H, Taketomi E, Ikari K, Komiya S, et al. Functional impact of human collagen α2(XI) gene polymorphism in pathogenesis of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res. 2001;16:948–57.PubMedCrossRef
82.
Wei W, He HL, Chen CY, Zhao Y, Jiang HL, Liu WT, et al. Whole exome sequencing implicates PTCH1 and COL17A1 genes in ossification of the posterior longitudinal ligament of the cervical spine in Chinese patients. Genet Mol Res. 2014;13:1794–804.PubMedCrossRef
83.
Nakamura I, Ikegawa S, Okawa A, Okuda S, Koshizuka Y, Kawaguchi H, et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet. 1999;104:492–7.PubMedCrossRef
84.
Koshizuka Y, Kawaguchi H, Ogata N, Ikeda T, Mabuchi A, Seichi A, et al. Nucleotide pyrophosphatase gene polymorphism associated with ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res. 2002;17:138–44.PubMedCrossRef
85.
Ogata N, Koshizuka Y, Miura T, Iwasaki M, Hosoi T, Shiraki M, et al. Association of bone metabolism regulatory factor gene polymorphisms with susceptibility to ossification of the posterior longitudinal ligament of the spine and its severity. Spine. 2002;27:1765–71.PubMedCrossRef
86.
Kim KT, Lee SH, Kwack YH, Son ES, Park KJ, Kim DH. Association of estrogen receptor 2 (ESR 2) gene polymorphisms with ossification of the posterior longitudinal ligament of the spine. J Korean Soc Spine Surg. 2012;19:1–7.CrossRef
87.
Jun JK, Kim SM. Association study of fibroblast growth factor 2 and fibroblast growth factor receptors gene polymorphism in Korean ossification of the posterior longitudinal ligament patients. J Korean Neurosurg Soc. 2012;52:7–13.PubMedPubMedCentralCrossRef
88.
Sakou T, Taketomi E, Matsunaga S, Yamaguchi M, Sonoda S, Yashiki S. Genetic study of ossification of the posterior longitudinal ligament in the cervical spine with human leukocyte antigen haplotype. Spine. 1991;16:1249–52.PubMedCrossRef
89.
Matsunaga S, Yamaguchi M, Hayashi K, Sakou T. Genetic analysis of ossification of the posterior longitudinal ligament. Spine. 1999;24:937–9.PubMedCrossRef
90.
Kim KT, Kim DH, Chung JY, Lee S, Joo J, Nah SS, et al. Association of interferon gamma polymorphism with ossification of the posterior longitudinal ligament in the korean population. Immunol Invest. 2012;41:876–87.PubMedCrossRef
91.
Kim DH, Jeong YS, Chon J, Yoo SD, Kim HS, Kang SW, et al. Association between interleukin 15 receptor, alpha (IL15RA) polymorphism and Korean patients with ossification of the posterior longitudinal ligament. Cytokine. 2011;55:343–6.PubMedCrossRef
92.
Guo Q, Lv S-Z, Wu S-W, Tian X, Li Z-Y. Association between single nucleotide polymorphism of IL15RA gene with susceptibility to ossification of the posterior longitudinal ligament of the spine. J Orthop Surg Res. 2014;9:103.PubMedPubMedCentralCrossRef
93.
Lim JJ, Shin DA, Jeon YJ, Kumar H, Sohn S, Min HS, et al. Association of miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms with ossification of the posterior longitudinal ligament of the cervical spine. PLoS ONE. 2016;11: e0159756.PubMedPubMedCentralCrossRef
94.
Lee CH, Kim KT, Kim CH, Lee EY, Lee SG, Seo ME, et al. Unveiling the genetic variation of severe continuous/mixed-type ossification of the posterior longitudinal ligament by whole-exome sequencing and bioinformatic analysis. Spine J. 2021;21:1847–56.PubMedCrossRef
95.
Liu Y, Zhao Y, Chen Y, Shi G, Yuan W. RUNX2 polymorphisms associated with OPLL and OLF in the Han population. Clin Orthop Relat Res. 2010;468:3333–41.PubMedPubMedCentralCrossRef
96.
Chang F, Li L, Gao G, Ding S, Yang J, Zhang T, et al. Role of Runx2 polymorphisms in risk and prognosis of ossification of posterior longitudinal ligament. J Clin Lab Anal. 2017;31: e22068.PubMedCrossRef
97.
Numasawa T, Koga H, Ueyama K, Maeda S, Sakou T, Harata S, et al. Human retinoic X receptor β: complete genomic sequence and mutation search for ossification of posterior longitudinal ligament of the spine. J Bone Miner Res. 1999;14:500–8.PubMedCrossRef
98.
Kamiya M, Harada A, Mizuno M, Iwata H, Yamada Y. Association between a polymorphism of the transforming growth factor-beta1 gene and genetic susceptibility to ossification of the posterior longitudinal ligament in Japanese patients. Spine. 2001;26:1264–6.PubMedCrossRef
99.
Jekarl DW, Paek CM, An YJ, Kim YJ, Kim M, Kim Y, et al. TGFBR2 gene polymorphism is associated with ossification of the posterior longitudinal ligament. J Clin Neurosci. 2013;20:453–6.PubMedCrossRef
100.
Kobashi G, Ohta K, Washio M, Okamoto K, Sasaki S, Yokoyama T, et al. FokI variant of vitamin D receptor gene and factors related to atherosclerosis associated with ossification of the posterior longitudinal ligament of the spine: a multi-hospital case-control study. Spine. 2008;33:E553–8.PubMedCrossRef
101.
Chin DK, Han IB, Ropper AE, Jeon YJ, Kim DH, Kim YS, et al. Association of VKORC1-1639G>A polymorphism with susceptibility to ossification of the posterior longitudinal ligament of the spine: a Korean study. Acta Neurochir. 2013;155:1937–42.PubMedCrossRef
102.
Tsukahara S, Miyazawa N, Akagawa H, Forejtova S, Pavelka K, Tanaka T, et al. COL6A1, the candidate gene for ossification of the posterior longitudinal ligament, is associated with diffuse idiopathic skeletal hyperostosis in Japanese. Spine. 2005;30:2321–4.PubMedCrossRef
103.
Parreira B, Couto AR, Rocha F, Sousa M, Faustino V, Power DM, et al. Whole exome sequencing of patients with diffuse idiopathic skeletal hyperostosis and calcium pyrophosphate crystal chondrocalcinosis. Acta Reumatol Port. 2020;45:116–26.PubMed
104.
Furushima K, Shimo-Onoda K, Maeda S, Nobukuni T, Ikari K, Koga H, et al. Large-scale screening for candidate genes of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res. 2002;17:128–37.PubMedCrossRef
105.
Han IB, Ropper AE, Jeon YJ, Park HS, Shin DA, Teng YD, et al. Association of transforming growth factor-beta 1 gene polymorphism with genetic susceptibility to ossification of the posterior longitudinal ligament in Korean patients. Genet Mol Res. 2013;12:4807–16.PubMedCrossRef
106.
Kawaguchi Y, Furushima K, Sugimori K, Inoue I, Kimura T. Association between polymorphism of the transforming growth factor-beta1 gene with the radiologic characteristic and ossification of the posterior longitudinal ligament. Spine. 2003;28:1424–6.PubMedCrossRef
107.
•• Kato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, et al. Identification of ENPP1 haploinsufficiency in patients with diffuse idiopathic skeletal hyperostosis and early-onset osteoporosis. J Bone Miner Res. 2022;37:1125–35. An important study documenting that heterozygous or compound heterozygous ENPP1 pathogenic variant could be the genetic factor for development of OPLL, DISH and early-onset osteoporosis.PubMedCrossRef
108.
•• Oheim R, Zimmerman K, Maulding ND, Stürznickel J, von Kroge S, Kavanagh D, et al. Human heterozygous ENPP1 deficiency is associated with early onset osteoporosis, a phenotype recapitulated in a mouse model of Enpp1 deficiency. J Bone Miner Res. 2020;35:528–39. An important study documenting that heterozygous ENPP1 pathogenic variant could be the genetic factor for development of early-onset osteoporosis.PubMedCrossRef
109.
Saetia K, Cho D, Lee S, Kim DH, Kim SD. Ossification of the posterior longitudinal ligament: a review. Neurosurg Focus. 2011;30:E1.PubMedCrossRef
110.
Kawaguchi Y, Nakano M, Yasuda T, Seki S, Suzuki K, Yahara Y, et al. Serum biomarkers in patients with ossification of the posterior longitudinal ligament (OPLL): inflammation in OPLL. PLoS ONE. 2017;12:1–13.CrossRef
111.
•• Kawaguchi Y, Kitajima I, Nakano M, Yasuda T, Seki S, Suzuki K, et al. Increase of the serum FGF-23 in ossification of the posterior longitudinal ligament. Global Spine J. 2019;9:492–8. An interesting study evaluating the association between serum FGF23 levels and OPLL.PubMedCrossRef
112.
Zimmerman K, Liu X, von Kroge S, Stabach P, Lester ER, Chu EY, et al. Catalysis-independent ENPP1 protein signaling regulates mammalian bone mass. J Bone Miner Res. 2022;37:1733–49.PubMedCrossRef
113.
Maulding ND, Kavanagh D, Zimmerman K, Coppola G, Carpenter TO, Jue NK, et al. Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization. Bone. 2021;142: 115656.PubMedCrossRef
114.
Jacobs IJ, Cheng Z, Ralph D, O’Brien K, Flaman L, Howe J, et al. INZ-701, a recombinant ENPP1 enzyme, prevents ectopic calcification in an Abcc6−/− mouse model of Pseudoxanthomaelasticum. Exp Dermatol Exp Dermatol. 2022;31:1095–101.PubMedCrossRef
115.
Ikegawa S, Kurokawa T, Hizuka N, Hoshino Y, Ohnishi I, Shizumet K. Increase of serum growth hormone-binding protein in patients with ossification of the posterior longitudinal ligament of the spine. Spine. 1993;18:1757–60.PubMedCrossRef
116.
Goto K, Yamazaki M, Tagawa M, Goto S, Kon T, Moriya H, et al. Involvement of insulin-like growth factor I in development of ossification of the posterior longitudinal ligament of the spine. Calcif Tissue Int. 1998;62:158–65.PubMedCrossRef
117.
Maeda S, Koga H, Matsunaga S, Numasawa T, Ikari K, Furushima K, et al. Gender-specific haplotype association of collagen alpha2 (XI) gene in ossification of the posterior longitudinal ligament of the spine. J Hum Genet. 2001;46:1–4.PubMedCrossRef
118.
Albright RA, Stabach P, Cao W, Kavanagh D, Mullen I, Braddock AA, et al. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nat Commun. 2015;6:10006.PubMedCrossRef
119.
Bernhard E, Nitschke Y, Khursigara G, Sabbagh Y, Wang Y, Rutsch F. A reference range for plasma levels of inorganic pyrophosphate in children using the ATP sulfurylase method. J Clin Endocrinol Metab. 2022;107:109–18.PubMedCrossRef
Bei Fragilitätsfrakturen im Alter kommt es auf weit mehr an als auf die anatomische Rekonstruktion. Die Dresdner Orthopädin Dr. Anne Postler zeigte beim Ortho Trauma Update, was für die Versorgung wichtig ist: vom OP-Timing über die Delirprävention bis hin zur Osteoporosetherapie.
In einer finnischen Bevölkerungsstudie zeigten fast alle Teilnehmenden in der MRT mindestens eine Anomalie an der Rotatorenmanschette, unabhängig davon, ob sie Beschwerden an der Schulter hatten oder nicht. Der Wert einer routinemäßigen Bildgebung ohne vorangegangenes Trauma erscheint in diesem Zusammenhang fraglich.
Gedanken an eine Selbsttötung gehen Ärztinnen und Ärzten vergleichsweise häufig durch den Kopf. Hilfe wäre möglich, wird aber selten gesucht. Warum eigentlich?
Ärzte und Psychotherapeuten mit einem neuen Heilberufsausweis der Generation 2.1 müssen diesen jetzt mitunter nochmals tauschen. Die KBV appelliert an die Betroffenen, der Aufforderung ihres Anbieters nachzukommen und umgehend eine Austauschkarte zu beantragen.
